Read more: CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative...
Read more: CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative...
Read more: Treadwell Therapeutics Announces a Presentation at the 2023 ASH Annual Meeting and Advisory Board Meeting
Continue reading here: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
See original here: Fresh Tracks Therapeutics Announces Third Adjournment of Special Meeting of Stockholders
Originally posted here: Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
View post: FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
See more here: Blueberries Medical Announces C$2 Million Non-Brokered Private Placement
See the article here: Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
Here is the original post: Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
Excerpt from: Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
Recent Comments